BioWorld MedTech

Aug. 5, 2015

View Archived Issues

Drugs enter third dimension: First FDA approval in hand, Aprecia looks to alter drug delivery with 3-D printing

Less is More with MIS Lipoplasty: Lipoplasty market attractive for both small and large players

Inside the Beltway: IPPS final rule receives mostly favorable reviews for med-tech DRGs

Daily M&A: Boston Scientific closes $1.65B buy of the AMS Male Urology Portfolio

Financings: Novacyt secures flexiblefunding, up to 5 million

HIT Bits: PhysIQ personalized physiology analytics receives FDA clearance

People in places

Products

MDD's Oncology Extra

Sour IPO Transforms into Sweet JV: Mevion scraps IPO plans but raises $200M and strikes a JV deal with Chinese investors

A proton therapy systems provider has canceled its plans to go public and now plans to form a joint venture (JV) in China supported by a new investment agreement worth up to $200 million. Read More

Resmed finds sleeper opportunity: Resmed wakes up to potential of huge Chinese sleep disorder market

Today's news in brief

BioWorld

Illustration of SCAN in Parkinson’s vs healthy subcortex

SCAN is core circuit affected in Parkinson’s disease

BioWorld

Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...

3D rendering of skin cells and elastin with collagen layer

First-in-class pan-inflammasome blocker for hidradenitis suppurativa

BioWorld Science

Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.

Illustration of cancer cell in crosshairs being destroyed

RX-10616 improves radiotherapy efficacy in HNSCC

BioWorld Science

Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...

CROI 2026: Neurodegeneration, the challenge of aging with HIV

BioWorld

Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...